Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point them out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment options (if involved); it does not constitute any investment advice.
On July 28, 2025, Zhongmou Therapeutics (Wuhan) Co., Ltd. ("Zhongmou Therapeutics"), a global clinical-stage ophthalmic gene therapy innovator, announced the signing of a new round of financing agreement worth tens of millions. The lead investor and co-investors of this round are all well-known investment institutions in China, with other investment institutions still in negotiations to join, and the scale of this round of financing is expected to further expand. The proceeds from this financing will be mainly used to accelerate...Core Product ZM-02The global multicenter clinical trials and subsequent pipeline development further solidify the company's leading position in the field of ophthalmic gene therapy.Breakthrough Therapy Receives International Recognition, Clinical Data Shows Outstanding PerformanceZhongmou Therapeutics' core product, ZM-02, is a broad-spectrum optogenetic gene therapy. The results of its first-in-human clinical study (MOON: NCT06292650) showed that the therapy significantly improved vision and quality of life in patients with retinitis pigmentosa (RP). With its innovative therapeutic mechanism and significant clinical potential, ZM-02 received orphan drug designation from the U.S. FDA in October 2024, and the first human clinical study data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May this year, drawing high industry attention.Professor Shen Yin, founder and chief scientist of Zhongmou Therapeutics, stated"Thanks to the strong support from both new and existing investors. This round of financing is an important milestone for the development of Zhongmou Therapeutics. We will accelerate the clinical progress of our core pipeline, continue to expand our R&D pipeline, and work with global partners to drive breakthroughs in ophthalmic gene therapy, realizing the vision of 'a world without blindness' as soon as possible."About Zhongmou TherapeuticsZhongmou Therapeutics has a globally leading comprehensive platform system for optogenetic gene therapy, dedicated to extending innovative treatments to patients with degenerative retinal diseases worldwide. The optogenetic gene therapy approach involves delivering genes encoding light-sensitive proteins to retinal cells via an AAV vector, enabling the retina to express a special functional protein sensitive to light. These light-sensitive proteins are activated by natural external light and generate visual signals that are transmitted to the brain, thereby restoring vision and improving the patient's eyesight.Zhongmou Therapeutics' optogenetic gene therapy product is a revolutionary treatment that effectively helps restore vision in blind or visually impaired patients through intravitreal injection. Its core advantages are: 1) It is a drug therapy focused on functional recovery and vision improvement; 2) Broad-spectrum and not limited by specific gene mutation sites, targeting all blindness caused by retinal photoreceptor cell apoptosis; 3) A single optogenetic gene therapy can safely and effectively achieve long-term or even lifelong vision improvement.Source of the article:Zhongmou Therapeutics
